文献速递神经肿瘤

LINC00152通过LINC00152/miR-107/RAB10轴促进胶质瘤增殖与侵袭并作为潜在标志物

LINC00152 acts as a potential marker in gliomas and promotes tumor proliferation and invasion through the LINC00152/miR-107/RAB10 axis.
PubMed 文献 · J Neurooncol · 2021-09-03

该研究探讨长链非编码RNA LINC00152在胶质母细胞瘤中的生物学作用与分子机制。研究发现LINC00152在胶质瘤中上调,与高侵袭性和不良预后相关;敲低LINC00152可抑制增殖、侵袭并诱导凋亡,体内抑制成瘤。机制上LINC00152作为miR-107海绵调控RAB10,沉默miR-107可逆转敲低效应。

要点

  • LINC00152在胶质瘤中上调,与高侵袭性和不良预后相关。
  • 敲低LINC00152抑制胶质瘤细胞增殖、侵袭并诱导凋亡,体内抑制成瘤。
  • LINC00152通过海绵吸附miR-107调控RAB10,该轴或为治疗靶点。

核心结论

  • LINC00152是胶质瘤候选预后标志物,LINC00152/miR-107/RAB10轴在调控胶质瘤恶性行为中起关键作用,靶向该轴可能为有效治疗策略。

研究设计与样本

  • 研究采用生物信息学分析结合体外实验(CCK-8、集落形成、流式细胞术、Matrigel侵袭、划痕愈合、Western blot)及小鼠异种移植模型。

主要发现

  • LINC00152在胶质瘤中上调,其表达与高肿瘤侵袭性和患者不良结局显著相关。
  • 敲低LINC00152在体外抑制胶质瘤细胞增殖和侵袭并诱导凋亡,在体内抑制成瘤。
  • 生物信息学与实验证实LINC00152和RAB10为miR-107的靶标,LINC00152可能作为miR-107海绵调控RAB10表达。
  • 沉默miR-107可逆转LINC00152敲低对胶质母细胞瘤细胞在体外和体内的效应。

临床怎么用

  • LINC00152或可作为胶质瘤预后评估的候选分子标志物。
  • 靶向LINC00152/miR-107/RAB10轴可能为胶质瘤治疗提供新策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Aberrant expression of long noncoding RNAs plays a pivotal role in tumorigenesis. Recently, several studies have showed that the LINC00152 gene is upregulated in a variety of tumors and plays an oncogene role; however, its underlying molecular mechanisms in glioblastoma remain unclear. In this study, we prepare to investigate the biological role and underlying molecular mechanisms of LINC00152 in glioblastoma cells. METHODS: Bioinformatics analysis to identify LINC00152 expression, Cell Counting kit-8 assay and Colony formation assay were used to evaluate proliferation, Flow cytometric analysis was used to evaluate apoptosis, Cell Matrigel invasion assay and Wound healing assay was used to evaluate invasion, Western blot analysis to check protein expression level, Mouse xenograft models was used to check cell proliferation in vivo. RESULTS: In this study, we found that LINC00152 was upregulated in gliomas and its expression was significantly associated with high tumor aggressiveness and poor outcomes for glioma patients. Functionally, the knockdown of LINC00152 not only inhibited malignant behaviors of glioma, such as proliferation and invasion of glioma cells and induced apoptosis in vitro but also suppressed tumorigenesis in vivo. Mechanistically, results of the bioinformatics analysis and experimental studies confirmed that LINC00152 and RAB10 as the targets of miR-107, and LINC00152 might act as a sponge for miR-107 to regulate the expression of RAB10 in glioblastoma. Additionally, silencing miR-107 reversed the effects induced by LINC00152 knockdown on glioblastoma cells both in vitro and in vivo. CONCLUSION: Our data suggested that LINC00152 is a candidate prognostic marker of glioma, and that the LINC00152/MIR-107/RAB10 axis plays a pivotal role in regulation of the glioma malignancy, and therefore, targeting the axis might be an effective therapeutic strategy to treat glioma.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Peng G, Su J, Xiao S, et al. LINC00152 acts as a potential marker in gliomas and promotes tumor proliferation and invasion through the LINC00152/miR-107/RAB10 axis. J Neurooncol. 2021. PMID: 34478013. doi:10.1007/s11060-021-03836-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。